Sev­er­al biotech col­leagues and I were in­spired by the Neu­ro­science Lab at Cold Spring Har­bor’s clever and strik­ing pro-im­mi­gra­tion GIF an­i­ma­tion. We thought a sim­i­lar pho­to wall on be­half of the biotech/life sci­ences com­mu­ni­ty would be a grip­ping state­ment that’s hard to look away. Here’s a su­per start.

Want to add your com­pa­ny to this col­lec­tion? Use the icon next to my by­line to send an email.

Akcea

Al­ny­lam

Deci­bel

De­nali

Geno­cea

Mor­phic

NGM Bio

Ovid

Pax­Vax

Schro­ding­er

Xen­cor

Praveen Tipir­neni is the CEO of Mor­phic Ther­a­peu­tic. Biotech Voic­es is a con­tributed col­umn writ­ten by se­lect End­points News sub­scribers.

Roche had big plans for etrolizumab. Eyeing a hyper-competitive IBD and Crohn’s market where they have not historically been a player, the company rolled out 8 different Phase III trials, testing the antibody for two different uses across a range of different patient groups.

On Monday, Roche released results for 4 of those studies, and they mark a decided setback for both the Swiss pharma and their biotech sub Genentech, potentially spelling an end to a drug they put over half-a-decade and millions of dollars behind.

The lead program for AnaptysBio’s in-house pipeline has hit another setback.

Etokimab, an IL-33 inhibitor, did not achieve statistically significant improvement in a Phase II trial for patients suffering from chronic rhinosinusitis with nasal polyps. Researchers measured the individuals’ bilateral nasal polyps score and sino-nasal outcome test, finding that neither improved upon a placebo after both four- and eight-week time markers, though they did demonstrate improvement over baseline levels of the examinations.

When Infinity put up duvelisib for a no-money-down instant deal, the biotech was looking for a quick exit from a clinical disaster. AbbVie had walked away from their alliance after looking at how the data stacked up in a crowded field.

And while it was approvable, it wasn’t looking pretty to anyone who thought in commercial terms.

One Big Pharma’s trash, though, was seen as a biotech treasure as a deeply troubled Verastem stepped up to grab the PI3K-delta/gamma — promising to run it across the goal lines at the FDA. And they did just that, only with little to show for it.

Dyne Therapeutics started out last April with a modest $50 million to mine targeted muscle disease therapies from its in-house conjugate technology. The biotech has now convinced more investors that it’s got gems on its hands, closing $115 million in fresh financing to push its next-gen oligonucleotide drugs into the clinic.

Vida Ventures and Surveyor Capital led the round, joined by a group of other new backers including Wellington Management Company, Logos Capital and Franklin Templeton.